Other compounds

RU-58841: molecular data, studies & sources

RU-58841 is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked 2026-10-09 · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF): C17H18F3N3O3
Molecular weight (MW): 369.34 g/mol
PubChem compound ID: 132981
Record title: 4-(3-(4-Hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl)-2-(trifluoromethyl)benzonitrile

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 132981 · retrieved 2026-10-09

2D molecular structure for RU-58841, PubChem CID 132981 — 2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.

Chemical identifiers and source data

IUPAC name: 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
InChIKey: ARBYGDBJECGMGA-UHFFFAOYSA-N
SMILES: CC1(C(=O)N(C(=O)N1CCCCO)C2=CC(=C(C=C2)C#N)C(F)(F)F)C

Machine-readable PubChem source

Identifiers

PubChem CID: 132981
CAS Registry Number: 154992-24-2via ChemIDplus, EPA DSSTox, FDA GSRS
FDA UNII: 0D8FJQ0ADW
ChEMBL ID: CHEMBL9337
InChIKey: ARBYGDBJECGMGA-UHFFFAOYSA-N
Wikidata: Q16943512

CAS numbers are published only from ChemIDplus, EPA DSSTox or the FDA Global Substance Registration System; UNII codes are confirmed in FDA GSRS by structure, sequence or exact name. Checked 2026-10-09.

Calculated molecular descriptors

Monoisotopic (exact) mass	369.1300 Da
Heavy atoms	26
Hydrogen-bond donors	1
Hydrogen-bond acceptors	4
Rotatable bonds	5
Topological polar surface area	84.6 Å²
Calculated logP (Crippen)	2.90
Rings	2
Stereocenters	0
Formal charge	0

Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.

Registered clinical trials

Studies registered on ClinicalTrials.gov that list RU-58841 as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

No registered study naming this compound was matched. This is a documented gap in registry coverage, not proof that no study exists.

Registry check 2026-10-01 · Run this search on ClinicalTrials.gov

Human intervention studies

Selected studies in which participants received RU-58841, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.

No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

Preclinical / laboratory research
Local inhibition of sebaceous gland growth by topically applied RU 58841.
Matias JR, Gaillard M · Annals of the New York Academy of Sciences · 1995
PMID 7625751 · DOI: 10.1111/j.1749-6632.1995.tb31369.x
Preclinical / laboratory research
RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism.
Battmann T, Bonfils A, Branche C et al. · The Journal of steroid biochemistry and molecular biology · 1994
PMID 8136306 · DOI: 10.1016/0960-0760(94)90250-x
Research publication · design requires review
Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques.
Pan HJ, Wilding G, Uno H et al. · Endocrine · 1998
PMID 9798729 · DOI: 10.1385/ENDO:9:1:39
Research publication · design requires review
RU 58841-myristate--prodrug development for topical treatment of acne and androgenetic alopecia.
Münster U, Nakamura C, Haberland A et al. · Die Pharmazie · 2005
PMID 15700772
Research publication · design requires review
Investigation Into the Metabolism and Elimination Behavior of RU 58841, and Its Influence on the Steroid Profile in Humans.
Okutan A, Krug O, Fußhöller G et al. · Biomedical chromatography : BMC · 2026
PMID 42615108 · DOI: 10.1002/bmc.70602
Research publication · design requires review
A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice.
De Brouwer B, Tételin C, Leroy T et al. · The British journal of dermatology · 1997
PMID 9415227

RU-58841 supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

No priced supplier offers are currently available in this catalog view. The research record remains available independently of stock.

Reference sources & further reading

PubChem compound record 132981 — chemical identity and structure.
FDA Global Substance Registration System: UNII 0D8FJQ0ADW — substance identity, names and codes.

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.